Knockdown of PAK4 or PAK1 inhibits the mroliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling

Molecular Cancer Research

Volumn 11, Issue 2, 2013, Pages 109-121

  Tabusa, Hana ^a   Brooks, Teresa ^a   Massey, Andrew J ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ACTIN; CASPASE; COFILIN; K RAS PROTEIN; LIM KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 4; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAF PROTEIN;

ACTIN FILAMENT; ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ANCHORAGE; CELL CYCLE ARREST; CELL DEATH; CELL ELONGATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SPHEROID CELL;

CELL GROWTH PROCESSES; COLONIC NEOPLASMS; GENES, RAS; HCT116 CELLS; HT29 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; P21-ACTIVATED KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 84874424655     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0466     Document Type: Article

References (45)

1. Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell 2008;100: 97-108.
2. Eswaran J, Soundararajan M, Kumar R, Knapp S. UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci 2008;33:394-403.
3. Wells CM, Jones GE. The emerging importance of group II PAKs. Biochem J 2010;425:465-73.
4. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 2009;28:209-17.
5. Li X, Minden A. PAK4 functions in tumor necrosis factor (TNF) alphainduced survival pathways by facilitating TRADD binding to the TNF receptor. J Biol Chem 2005;280:41192-200.
6. Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 2000;20:453-61.
7. Qu J, Cammarano MS, Shi Q, Ha KC, De Lanerolle P, Minden A. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol 2001;21:3523-33.
8. Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal 2008;20:1320-8.
9. Whale A, Hashim FN, Fram S, Jones GE, Wells CM. Signalling to cancer cell invasion through PAK family kinases. Front Biosci 2011;16: 849-64.
10. Coniglio SJ, Zavarella S, Symons MH. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol Cell Biol 2008;28:4162-72.
11. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 2002;277:550-8.
12. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, et al. Regulatableexpressionofp21-activatedkinase-1 promotesanchorageindependent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000;275:36238-44.
13. Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford P, Reeve A, et al. P21-activated kinase 1: A new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol 2007;178: 1073-9.
14. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A 2011;108:7177-82.
15. CarterJH,DouglassLE,DeddensJA,ColliganBM,BhattTR,Pemberton JO, et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004;10:3448-56.
16. Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 2008;47:481-9.
17. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006;25:2931-6.
18. Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A 2008;105: 19372-7.
19. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, et al. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res 2008;6:1215-24.
20. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, et al. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A 2010;107:18622-7.
21. Abo A, Qu J, Cammarano MS, Dan C, Fritsch A, Baud V, et al. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J 1998;17: 6527-40.
22. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
23. Li LH, Zheng MH, Luo Q, Ye Q, Feng B, Lu AG, et al. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol 2010;37:951-62.
24. Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget 2011;2:491-6.
25. Kichina JV, Goc A, Al Husein B, Somanath PR, Kandel ES. PAK1 as a therapeutic target. Expert Opin Ther Targets 2010;14:703-25.
26. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A 2010;107:9446-51.
27. Huynh N, Liu KH, Baldwin GS, He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK-and AKTdependent pathways. Biochim Biophys Acta 2010;1803:1106-13.
28. He H, Huynh N, Liu KH, Malcontenti-Wilson C, Zhu J, Christophi C, et al. P-21 activated kinase 1 knockdown inhibits beta-catenin signalling and blocks colorectal cancer growth. Cancer Lett 2012;317:65-71.
29. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: Considerations and practical approach. Nat Protoc 2009;4:309-24.
30. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. The Wnt/betacatenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010;9:212.
31. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
32. Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15: 1126-32.
33. Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, et al. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis 2011;32:765-71.
34. Ahn HK, Jang J, Lee J, Se Hoon P, Park JO, Park YS, et al. P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Transl Oncol 2011;4:345-9.
35. Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, Du J, et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 2012;31:3397-408.
36. Liu F, Li X, Wang C, Cai X, Du Z, Xu H, et al. Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer 2009;125:2511-9.
37. Baskaran Y, Ng YW, Selamat W, Ling FT, Manser E. Group I and II mammalian PAKs have different modes of activation by Cdc42. EMBO Rep 2012;13:653-9.
38. Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem 2001;276:14414-9.
39. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71.
40. Park ER, Eblen ST, Catling AD. MEK1 activation by PAK: A novel mechanism. Cell Signal 2007;19:1488-96.
41. Zhang J,WangJ,GuoQ,WangY, Zhou Y, Peng H, et al. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett 2011;317:24-32.
42. Zang M, Hayne C, Luo Z. Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J Biol Chem 2002;277:4395-405.
43. Koh W, Sachidanandam K, Stratman AN, Sacharidou A, Mayo AM, MurphyEA, et al. Formation of endothelial lumensrequiresa coordinated PKCepsilon-, Src-, Pak-and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. J Cell Sci 2009;122:1812-22.
44. Dan C, Kelly A, Bernard O, Minden A. Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem 2001;276:32115-21.
45. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIMkinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1999;1:253-9.